Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-CHOP in DLBCL
NCT00386321Phase 2Terminated
- Sponsor
- Chulalongkorn University
- Start
- Apr 2006
- Primary completion
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Chulalongkorn University. Primary endpoints: Progression-Free Survival at 2 years and Overall Survival at 2 years. Started Apr 2006; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00386321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386321.